RÉSUMÉ
Chronic inflammation is a major cause of cancer worldwide. Interleukin 33 (IL-33) is a critical initiator of cancer-prone chronic inflammation; however, its induction mechanism by environmental causes of chronic inflammation is unknown. Herein, we demonstrate that Toll-like receptor (TLR)3/4-TBK1-IRF3 pathway activation links environmental insults to IL-33 induction in the skin and pancreas inflammation. An FDA-approved drug library screen identifies pitavastatin to effectively suppress IL-33 expression by blocking TBK1 membrane recruitment/activation through the mevalonate pathway inhibition. Accordingly, pitavastatin prevents chronic pancreatitis and its cancer sequela in an IL-33-dependent manner. The IRF3-IL-33 axis is highly active in chronic pancreatitis and its associated pancreatic cancer in humans. Interestingly, pitavastatin use correlates with a significantly reduced risk of chronic pancreatitis and pancreatic cancer in patients. Our findings demonstrate that blocking the TBK1-IRF3-IL-33 signaling axis suppresses cancer-prone chronic inflammation. Statins present a safe and effective prophylactic strategy to prevent chronic inflammation and its cancer sequela.
Sujet(s)
Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase , Facteur-3 de régulation d'interféron , Interleukine-33 , Tumeurs du pancréas , Protein-Serine-Threonine Kinases , Quinoléines , Transduction du signal , Interleukine-33/métabolisme , Animaux , Facteur-3 de régulation d'interféron/métabolisme , Humains , Tumeurs du pancréas/prévention et contrôle , Tumeurs du pancréas/métabolisme , Tumeurs du pancréas/génétique , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/pharmacologie , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Souris , Protein-Serine-Threonine Kinases/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Quinoléines/pharmacologie , Quinoléines/usage thérapeutique , Inflammation/prévention et contrôle , Inflammation/métabolisme , Pancréatite chronique/prévention et contrôle , Pancréatite chronique/métabolisme , Récepteur de type Toll-3/métabolisme , Souris de lignée C57BL , Récepteur de type Toll-4/métabolisme , Acide mévalonique/métabolisme , Mâle , Femelle , Souris knockoutRÉSUMÉ
Many pediatric oncology patients and their families may benefit from genetic counseling and testing; however, identifying the best timing and delivery method for these referrals is sometimes a challenge. The goal of this study was to understand how and when caregivers prefer to receive information about genetic counseling and testing. A total of 56 surveys completed by caregivers at The Johns Hopkins Hospital Pediatric Oncology unit in Baltimore, Maryland were analyzed. A sizeable subset of respondents was interested in receiving information about the availability of genetic counseling from an oncology doctor or nurse, but not a genetic counselor (n=13/55, 24%). Most respondents preferred to be informed about genetic services at diagnosis (n=28/54, 52%) or within 1 to 2 months of diagnosis (n=14/54, 26%). In conclusion, patients and their families may benefit from prompt and early recognition of the risk of cancer predisposition syndromes, preferably within the first 2 months following diagnosis. Oncology professionals are an important source of information, and can introduce the availability of genetic counseling services and motivate families to undergo genetic testing, though alternative communication methods such as brochures may also be useful.
